Early Stage I-II (A-B) Prostate Cancer

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (10-3-2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (04-25-2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (02-22-2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (11-5-2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer.... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (08-17-2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients (08-5-2015)

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic Prostate Score (GPS) in treatment planning... Continue Reading

More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression (07-15-2015)

Increasingly more men with low-risk, early-stage prostate cancer appear to choose active surveillance (or watchful waiting) instead of treatment. As a result, they’re avoiding the risk of long-term side effects of treatment. These findings were reported... Continue Reading

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations (12-10-2014)

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment... Continue Reading

New Survey Reveals Alarming Lack of Understanding of Prostate Cancer (11-18-2014)

(OMNI-CancerConnect) In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic... Continue Reading

American Society of Clinical Oncology Endorses AUA/ASTRO Guidelines on the Use of Radiation Treatment After Prostatectomy (11-11-2014)

The American Society of Clinical Oncology (ASCO) issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guidelines on the use of adjuvant and salvage radiotherapy after prostatectomy, which was... Continue Reading

Next Page »